News
  Date Title View
Jul 6, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of th...
Jul 27, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"), announced today that its second quarter 2016 financial results will be released after the market closes on Wednesday, August 3, 2016. Following the release, the Company will host a live conference call and webcast at ...
Aug 3, 2016
NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02% On Schedule for Filing This Quarter Mercury 1 Phase 3 Topline Readout for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Expected in September 2016 Conference Call and Webcast Today, August 3,...
Aug 4, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of t...
Sep 6, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its N...
Sep 14, 2016
RoclatanTM Successfully Achieves Primary Efficacy Endpoint in Mercury 1 Study Conference Call and Webcast Today, September 14, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused...
Sep 15, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a...
Sep 16, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a regist...
Sep 28, 2016
Webcast to Begin at 12:00p.m. Eastern Time IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. ...
Oct 25, 2016
IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the "Company"), announced today that its third quarter 2016 financial results will be released after the market closes on Wednesday, November 2, 2016. Following the release, the Company will host a live conference call and webcast at ...
Page:
1
NextLast
= add release to Briefcase